🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Additive Anti-inflammatory Action for Aortopathy & Arteriopathy

Recruitingn/aAges 18 Years - anyAllNanjing Medical University
NCT04398992 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Acute aortic syndrome (AAS) is a life-threatening condition. Inflammation plays a key role in the pathogenesis, development and progression of AAS, and is associated with significant mortality and morbidity. Understanding the inflammatory responses and inflammation resolutions is essential for an appropriate management of AAS. Twenty Chinese cardiovascular centers have collaborated to create a multicenter observational registry (named Chinese registry of Additive Anti-inflammatory Action for Aortopathy \& Arteriopathy \[5A\]), with consecutive enrollment of adult patients who underwent surgery for AAS that was started on Jan 1, 2016 and will be ended on December 31, 2040. Specially, the impact of inflammation and anti-inflammatory strategies on the early and late adverse events are investigated. Primary outcomes are severe systemic inflammatory response syndrome (SIRS), multiple organ d

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion criteria * Aged 18 years or older. * Patients with diagnosis of AAS, including aortic dissection, penetrating aortic ulcer or intramural hematoma. * Symptoms started within 14 days from surgery. * Patients received medical therapy, open surgical, endovascular, or hybrid repair. * Any other major cardiac surgical procedure concomitant with surgery for AAS, such as coronary artery bypass grafting or carotid artery replacement; * The patient or guardian agrees to participate in this study. Exclusion criteria * Patients aged \< 18 years. * Onset of symptoms \> 14 days from surgery. * AAS secondary to traumatic or iatrogenic injury. * Patients who declined participation in registration and follow-up investigation.
💊

What it tests

  • observation
📍

Where

34 sites
Beijing Fuwai Hospital Chinese Academy of Medical Sciences
Beijing, China
Chongqing Hospital of Jiangsu Provincial People's Hospital
Chongqing, China
Guangdong Provincial People's Hospital
Guangzhou, China
The First Affiliated Hospital of Guangxi Medical University
Nanning, China
QianXiNan People's Hospital
Xingyi, China
The Second Affiliated Hospital of Harbin Medical University
Harbin, China
The Third Affiliated Hospital of Soochow University
Changzhou, China
Suqian Hospital of of Nanjing Medical University
Suqian, China

…and 26 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy